Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Operating Leases (Tables)

Operating Leases (Tables)

9 Months Ended

Sep. 30, 2019

The following table shows the lease costs for the three and nine months ended September 30, 2019 (in thousands):


	Three months ended		Nine months ended
	September 30,		September 30,
	2019		2019
Lease cost:
Operating lease cost	$	989	$	3,003
Short-term lease cost		62		230
	$	1,051	$	3,233

			Nine months ended
			September 30,
			2019
Other information:
Operating cash flows from operating leases (in thousands)			$	3,176

			September 30,
			2019

Weighted-average remaining lease term - operating leases			7.5 years
Weighted-average discount rate - operating leases			7.2%

Schedule of maturities of operating lease liabilities

The maturities of operating lease liabilities are as follows (in thousands):


	Operating leases

2019	$	1,003
2020		4,033
2021		4,077
2022		4,082
2023		3,775
after 2023		16,076
Total lease payments		33,046
Less: Imputed interest		(8,111)
Present value of lease liability	$	24,935

The Company has operating leases in relation to property for office and research facilities. The maximum lease term without activation of termination options is to 2041.